Renaissance Technologies LLC Has $867,000 Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Renaissance Technologies LLC raised its holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 23.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 606,285 shares of the company’s stock after acquiring an additional 113,566 shares during the quarter. Renaissance Technologies LLC owned about 0.49% of Mersana Therapeutics worth $867,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in MRSN. Wells Fargo & Company MN lifted its position in shares of Mersana Therapeutics by 40.3% in the 4th quarter. Wells Fargo & Company MN now owns 67,483 shares of the company’s stock worth $97,000 after acquiring an additional 19,368 shares during the period. SG Americas Securities LLC raised its stake in shares of Mersana Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock valued at $161,000 after purchasing an additional 25,058 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Mersana Therapeutics in the fourth quarter worth $37,000. Geode Capital Management LLC boosted its stake in Mersana Therapeutics by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 2,442,250 shares of the company’s stock worth $3,493,000 after buying an additional 29,035 shares in the last quarter. Finally, Avanza Fonder AB bought a new stake in Mersana Therapeutics in the 4th quarter valued at $81,000. 93.92% of the stock is owned by institutional investors.

Mersana Therapeutics Stock Performance

Shares of MRSN opened at $0.40 on Friday. The firm has a 50-day moving average of $0.40 and a 200-day moving average of $1.14. The company has a market cap of $49.85 million, a PE ratio of -0.66 and a beta of 1.68. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. Mersana Therapeutics, Inc. has a one year low of $0.26 and a one year high of $3.63.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. The business had revenue of $16.36 million for the quarter, compared to the consensus estimate of $7.71 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. As a group, equities analysts forecast that Mersana Therapeutics, Inc. will post -0.62 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on MRSN. William Blair started coverage on Mersana Therapeutics in a research report on Thursday, February 6th. They issued an “outperform” rating on the stock. Wedbush reaffirmed an “outperform” rating and issued a $4.00 target price on shares of Mersana Therapeutics in a report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Mersana Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $4.00.

Mersana Therapeutics Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.